BSX Boston Scientific Corp

  1. Stocks
  2. Healthcare
  3. NYSE: BSX

Price (delayed)

$42.6

Market cap

$61.74B

P/E Ratio

17.11

Dividend/share

N/A

EPS

$2.49

Enterprise value

$73.82B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: 72
Relative Profitability: Rel. Profitability: 88

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance ...

Highlights
The P/E is 74% below the 5-year quarterly average of 65.3 and 52% below the last 4 quarters average of 35.9
Boston Scientific's net income has increased by 47% YoY and by 3.1% QoQ
The equity has grown by 11% YoY but it has contracted by 3.6% from the previous quarter
BSX's quick ratio is down by 43% since the previous quarter and by 14% year-on-year
Boston Scientific's debt has increased by 14% QoQ and by 9% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bostonscientific.com
Peers: EW SYK MMSI MDT

Key stats

What are the main financial stats of BSX

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
-1.46%
1 week
-3.01%
1 month
-11.93%
1 year
-55.73%
YTD
-55.32%
QTD
-2.41%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$21B
Gross profit
$14.68B
Operating income
$4.15B
Net income
$3.68B
Gross margin
69.9%
Net margin
17.5%
Boston Scientific's net income has increased by 47% YoY and by 3.1% QoQ
Boston Scientific's operating income has increased by 32% YoY and by 9% from the previous quarter
Boston Scientific's net margin has increased by 30% YoY
Boston Scientific's gross profit has increased by 16% YoY and by 3% QoQ

Price vs fundamentals

How does BSX's price correlate with its fundamentals

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
BSX P/E details
P/E
17.11
P/B
2.54
P/S
2.98
EV/EBIT
17.45
EV/EBITDA
13.08
EV/Sales
3.52
The P/E is 74% below the 5-year quarterly average of 65.3 and 52% below the last 4 quarters average of 35.9
The EPS has increased by 46% YoY and by 3.3% from the previous quarter
The stock's price to book (P/B) is 46% less than its 5-year quarterly average of 4.7 and 44% less than its last 4 quarters average of 4.5
The equity has grown by 11% YoY but it has contracted by 3.6% from the previous quarter
BSX's P/S is 51% below its 5-year quarterly average of 6.1 and 46% below its last 4 quarters average of 5.5
The revenue has increased by 14% YoY

Efficiency

How efficient is Boston Scientific business performance
The return on assets has grown by 33% year-on-year
The return on equity has increased by 30% year-on-year
The ROS has increased by 12% YoY
BSX's ROIC is up by 12% YoY

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 126% more than its total liabilities
BSX's quick ratio is down by 43% since the previous quarter and by 14% year-on-year
BSX's current ratio is down by 35% since the previous quarter and by 9% year-on-year
Boston Scientific's debt is 49% lower than its equity
Boston Scientific's debt to equity has increased by 19% from the previous quarter
Boston Scientific's debt has increased by 14% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.